Renal-Cell Carcinoma

Cabozantinib a New First-Line Standard Therapy for High-Risk Advanced Renal-Cell Carcinoma?

Charles Bankhead

November 2016, Vol 7, No 10 - Renal-Cell Carcinoma

Copenhagen, Denmark—The current standard for the first-line targeted treatment of metastatic renal-cell carcinoma (RCC) came out on the short end of a randomized comparison with the new multikinase inhibitor cabozantinib (Cabometyx), according to results reported at the 2016 European Society for Medical Oncology Congress. [ Read More ]

Adjuvant Sunitinib Therapy Improves Outcomes in Clear-Cell Renal-Cell Carcinoma

Phoebe Starr

November 2016, Vol 7, No 10 - Renal-Cell Carcinoma

Copenhagen, Denmark—For the first time, a randomized clinical trial has shown that adjuvant therapy improves outcomes in patients with clear-cell renal-cell carcinoma (RCC). Adjuvant treatment with sunitinib (Sutent) improved disease-free survival (DFS) by >1 year in patients with high-risk locoregional RCC after nephrectomy, according to results from the S-TRAC clinical trial. Although this is encouraging news, at the 2016 European Society for Medical Oncology Congress some experts noted they were not ready to adopt it as a new standard of care, because of the associated toxicity and lack of an overall survival benefit. [ Read More ]